🔎 Trials Near Me

Akèy › Kansè nan tete › Kansas › Wichita

Etid klinik pou Kansè nan tete nan Wichita, KS

5 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Wichita (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Ap rekriteFaz 3
  • Cancer Center of Kansas, Wichita
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06982521

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Robert J Dole VA Medical Center, Wichita
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Ap rekriteFaz 3
  • Cancer Center of Kansas, Wichita
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Ap rekriteFaz 3
  • Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita
  • Ascension Via Christi Hospitals Wichita, Wichita
  • Cancer Center of Kansas - Wichita, Wichita
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Ap rekriteFaz 2
  • Cancer Center of Kansas, Wichita
Laj 18 ak plis · Tout sèks · Mizajou Nov 10, 2025 · NCT04553770

Etid Kansè nan tete nan lòt vil

Lòt etid nan Wichita

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.